PHK
KPTI icon

Point72 Hong Kong’s Karyopharm Therapeutics KPTI Stock Holding History

Point72 Hong Kong’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,941
Closed -$131K – 2176
2022
Q2 		$131K Buy
1,941
+1,910
+6,161% +$175K ﹤0.01% 1097
2022
Q1 		$3K Sell
31
-53
-63% -$6.61K ﹤0.01% 1714
2021
Q4 		$8K Sell
84
-634
-88% -$63.2K ﹤0.01% 1684
2021
Q3 		$63K Buy
+718
New +$74.5K ﹤0.01% 1468
2021
Q2 		– Sell
-20
Closed -$3K – 2146
2021
Q1 		$3K Buy
+20
New +$4.21K ﹤0.01% 1688
2020
Q4 		– Sell
-92
Closed -$20K – 1894
2020
Q3 		$20K Sell
92
-122
-57% -$29.8K ﹤0.01% 869
2020
Q2 		$61K Buy
214
+141
+193% +$41.7K 0.01% 710
2020
Q1 		$21K Buy
+73
New +$20.1K 0.01% 538
2019
Q3 		– Sell
-18
Closed -$2K – 1190
2019
Q2 		$2K Buy
+18
New +$1.45K ﹤0.01% 998
2018
Q4 		– Sell
-5
Closed -$1K – 1060
2018
Q3 		$1K Sell
5
-2
-29% -$553 ﹤0.01% 820
2018
Q2 		$2K Buy
+7
New +$1.73K ﹤0.01% 780
2018
Q1 		– Sell
-22
Closed -$3K – 1035
2017
Q4 		$3K Buy
+22
New +$3.53K ﹤0.01% 659

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Point72 Hong Kong's KPTI Position: Q3 2022 in Review

Point72 Hong Kong sold out of Karyopharm Therapeutics (KPTI) in Q3 2022, closing a stake of 1,941 shares — an estimated $131K sold.

Point72 Hong Kong first reported a position in KPTI in Q4 2017 and held it in 12 quarters. The position peaked at $131K in Q2 2022. 147 funds tracked by Wall St. Rank hold KPTI as of Q3 2022.

  • Point72 Hong Kong reported no remaining Karyopharm Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 1,941 Karyopharm Therapeutics shares in Q3 2022, an estimated $131K.
  • Point72 Hong Kong first reported a position in Karyopharm Therapeutics in Q4 2017 and held it in 12 quarters.
  • Point72 Hong Kong's Karyopharm Therapeutics position peaked at $131K in Q2 2022.
  • 147 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2022.

Based on Point72 Hong Kong's 13F filing for Q3 2022, filed 14 Nov 2022.